Modern medicine has a problem: despite impressive advances in technology, progress in drug development has slowed since the 1950s, as discovering and trialling new therapies has become more complex and expensive.
In this episode we explore how a convergence of healthcare technologies, and in particular artificial intelligence, promise to speed up and lower the cost of drug discovery and development—and the implications for medical breakthroughs and the economics of healthcare.
With guests Andrew Hopkins of Exscientia, Carina Namih of Episode1 Ventures, Peter Richardson of BenevolentAI, and industry advisor Steve Lipset.
Disclaimer: The findings and views expressed in the podcast are for information only and are not intended as an offer or solicitation or any legal, tax or financial advice. Whilst efforts have been taken to verify the accuracy of this information, neither The Economist Intelligence Unit Ltd., nor its affiliates, nor the Pictet Group can accept any responsibility or liability for the use of, or reliance by any person on, the information contained in this podcast. The findings and views expressed in the report do not necessarily reflect the views of the Pictet Group. The content of this podcast is not intended for persons who are citizens of, domiciled or resident in, or entities registered in a country or a jurisdiction in which its distribution, publication, provision or use would violate current laws and regulations.
Podden och tillhörande omslagsbild på den här sidan tillhör Economist Impact. Innehållet i podden är skapat av Economist Impact och inte av, eller tillsammans med, Poddtoppen.
